Investigation of the ALLEGRA THV System With a New Delivery System in Patients With Aortic Stenosis or Failed Surgical Bioprosthesis
A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 137 participants.
Also called NCT05478161
- Study
- In this atlas
Overview
- Design
- Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase
- Not applicable
- Enrolled
- 137 participants
- Sponsor
- NVT GmbH
- Registry
-
NCT05478161
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Germany, Netherlands, Spain
- Registry status
- Completed
Technical summary
Registry record NCT05478161. Allocation not applicable; no masking; primary purpose treatment. Start 2023-01-24 (actual); primary completion 2023-12-20 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Investigation of the ALLEGRA THV System With a New Delivery System in Patients With Aortic Stenosis or Failed Surgical Bioprosthesis
- Acronym
- EMPIRE
- Condition
- Transcatheter Aortic Valve Implantation
- Intervention (Device)
- (ALLEGRA Transcatheter Heart Valve) TAVI in severe calcified aortic stenosis or in failed surgical aortic bioprosthesis
- Lead sponsor
- NVT GmbH
Record details
- Record id
cardio:ct-nct05478161- Content hash
31fd4bf8a28d299cc52b662d7b6e2df1cd3f8f06995041f873027f6e50908a8a